These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38303927)

  • 21. Metabolic reprogramming of hypoxic tumor-associated macrophages through CSF-1R targeting favors treatment efficiency in colorectal cancers.
    Gharzeddine K; Gonzalez Prieto C; Malier M; Hennot C; Grespan R; Yamaryo-Botté Y; Botté CY; Thomas F; Laverriere MH; Girard E; Roth G; Millet A
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39317456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases.
    Alhudaithi SS; Almuqbil RM; Zhang H; Bielski ER; Du W; Sunbul FS; Bos PD; da Rocha SRP
    Mol Pharm; 2020 Dec; 17(12):4691-4703. PubMed ID: 33170724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer.
    Hollmén M; Karaman S; Schwager S; Lisibach A; Christiansen AJ; Maksimow M; Varga Z; Jalkanen S; Detmar M
    Oncoimmunology; 2016 Mar; 5(3):e1115177. PubMed ID: 27141367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
    Voissière A; Gomez-Roca C; Chabaud S; Rodriguez C; Nkodia A; Berthet J; Montane L; Bidaux AS; Treilleux I; Eberst L; Terret C; Korakis I; Garin G; Pérol D; Delord JP; Caux C; Dubois B; Ménétrier-Caux C; Bendriss-Vermare N; Cassier PA
    Sci Transl Med; 2024 Jan; 16(731):eadd1834. PubMed ID: 38266104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
    Manthey CL; Johnson DL; Illig CR; Tuman RW; Zhou Z; Baker JF; Chaikin MA; Donatelli RR; Franks CF; Zeng L; Crysler C; Chen Y; Yurkow EJ; Boczon L; Meegalla SK; Wilson KJ; Wall MJ; Chen J; Ballentine SK; Ott H; Baumann C; Lawrence D; Tomczuk BE; Molloy CJ
    Mol Cancer Ther; 2009 Nov; 8(11):3151-61. PubMed ID: 19887542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Depletion of tumor-associated macrophages enhances the anti-tumor effect of docetaxel in a murine epithelial ovarian cancer.
    Lu X; Meng T
    Immunobiology; 2019 May; 224(3):355-361. PubMed ID: 30926154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin.
    Pass HI; Lavilla C; Canino C; Goparaju C; Preiss J; Noreen S; Blandino G; Cioce M
    Oncotarget; 2016 Aug; 7(35):56408-56421. PubMed ID: 27486763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma.
    Toy EP; Chambers JT; Kacinski BM; Flick MB; Chambers SK
    Gynecol Oncol; 2001 Feb; 80(2):194-200. PubMed ID: 11161859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aging Leads to Increased Monocytes and Macrophages With Altered CSF-1 Receptor Expression and Earlier Tumor-Associated Macrophage Expansion in Murine Mesothelioma.
    Duong L; Pixley FJ; Nelson DJ; Jackaman C
    Front Aging; 2022; 3():848925. PubMed ID: 35821822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. M2pep-Modified Cyclodextrin-siRNA Nanoparticles Modulate the Immunosuppressive Tumor Microenvironment for Prostate Cancer Therapy.
    Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
    Mol Pharm; 2023 Nov; 20(11):5921-5936. PubMed ID: 37874541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy.
    Evrard D; Szturz P; Tijeras-Raballand A; Astorgues-Xerri L; Abitbol C; Paradis V; Raymond E; Albert S; Barry B; Faivre S
    Oral Oncol; 2019 Jan; 88():29-38. PubMed ID: 30616794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma.
    Erkes DA; Rosenbaum SR; Field CO; Chervoneva I; Villanueva J; Aplin AE
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):372-377. PubMed ID: 31696640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Colony Stimulating Factor-1 and its Receptor in Gastrointestinal Malignant Tumors.
    Li HW; Tang SL
    J Cancer; 2021; 12(23):7111-7119. PubMed ID: 34729112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSF-1R inhibition alters macrophage polarization and blocks glioma progression.
    Pyonteck SM; Akkari L; Schuhmacher AJ; Bowman RL; Sevenich L; Quail DF; Olson OC; Quick ML; Huse JT; Teijeiro V; Setty M; Leslie CS; Oei Y; Pedraza A; Zhang J; Brennan CW; Sutton JC; Holland EC; Daniel D; Joyce JA
    Nat Med; 2013 Oct; 19(10):1264-72. PubMed ID: 24056773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Colony-stimulating factor-1 receptor provides a growth advantage in epithelial cancer cell line A431 in the presence of epidermal growth factor receptor inhibitor gefitinib.
    Niehus SE; Tran DDH; Mischak M; Koch A
    Cell Signal; 2018 Nov; 51():191-198. PubMed ID: 30075184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Macrophage colony-stimulating factor and its role in the tumor microenvironment: novel therapeutic avenues and mechanistic insights.
    Yi L; Gai Y; Chen Z; Tian K; Liu P; Liang H; Xu X; Peng Q; Luo X
    Front Oncol; 2024; 14():1358750. PubMed ID: 38646440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of CSF-1R supports T-cell mediated melanoma therapy.
    Sluijter M; van der Sluis TC; van der Velden PA; Versluis M; West BL; van der Burg SH; van Hall T
    PLoS One; 2014; 9(8):e104230. PubMed ID: 25110953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7/8 Agonist To Repolarize Ovarian Tumors' Microenvironment.
    Kang Y; Flores L; Ngai HW; Cornejo YR; Haber T; McDonald M; Moreira DF; Gonzaga JM; Abidi W; Zhang Y; Hammad M; Kortylewski M; Aboody KS; Berlin JM
    Bioconjug Chem; 2021 Aug; 32(8):1581-1592. PubMed ID: 34289694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostaglandin E2 transactivates the colony-stimulating factor-1 receptor and synergizes with colony-stimulating factor-1 in the induction of macrophage migration via the mitogen-activated protein kinase ERK1/2.
    Digiacomo G; Ziche M; Dello Sbarba P; Donnini S; Rovida E
    FASEB J; 2015 Jun; 29(6):2545-54. PubMed ID: 25757564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
    Wiehagen KR; Girgis NM; Yamada DH; Smith AA; Chan SR; Grewal IS; Quigley M; Verona RI
    Cancer Immunol Res; 2017 Dec; 5(12):1109-1121. PubMed ID: 29097420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.